AN2 Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $150.84M
- P/E (TTM)
- –
- Dividend yield
- –
About AN2 Therapeutics
Pharmaceutical Preparations, SIC 2834
AN2 Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule therapeutics using its proprietary boron chemistry platform. Its research and clinical development pipeline spans hematologic conditions, infectious diseases, and oncology. The company's lead clinical candidate, epetraborole, is being developed for adult patients with phlebotomy-dependent polycythemia vera and individuals suffering from Mycobacterium abscessus complex lung disease. Another clinical asset, AN2-502998, targets patients with chronic Chagas disease. In addition, AN2 conducts global health initiatives aimed at addressing severe bacterial infections, such as melioidosis and tuberculosis, in underserved populations worldwide.
The company operates without internal production facilities, relying on specialized third-party contract manufacturers for raw materials, active drug substances, and finished trial products. Its clinical research and development activities take place across clinical study sites located in the United States and India. AN2 Therapeutics maintains its principal executive offices and corporate headquarters in Menlo Park, California.
Summary of the business section of AN2 Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- AN2 Therapeutics, Inc.
- Headquarters
- Menlo Park, CA
- Address
- 1300 El Camino Real, Suite 100 94025
- Phone
- (650) 331-9090
- Website
- an2therapeutics.com
- Employees
- 21, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- PricewaterhouseCoopers LLP, San Jose, California
Stock & identifiers
- Ticker
- ANTX
- Exchange
- Nasdaq
- IPO date
- Mar 28, 2022
- Shares outstanding
- 38M, Aug 6, 2026
- Public float
- $23.08M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- SEC CIK
- 1880438
- CUSIP
- 037326105
- ISIN
- US0373261058
- EIN
- 82-0606654
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Eric Easom | Chief Executive Officer, Director | 465,688 |
| Cameron C. Trenor III | Chief Medical Officer | 116,667 |
| Sarah Joanne Williams | Principal Accounting Officer | 66,311 |
| Joshua M. Eizen | See Remarks | 206,554 |
| Lucy Day | Chief Financial Officer | 118,363 |
| Sanjay Chanda | Chief Development Officer | 118,823 |
| Stephen David Prior | Chief Strategy Officer | 59,086 |
| Robin Shane Readnour | Director | 566,544 |
| Margaret M. FitzPatrick | Director | 10,708 |
| Joseph S. Zakrzewski | Director | 145,538 |
| Patricia A. Martin | Director | 18,863 |
| Gilbert Lynn Marks | Director | 81,873 |
| Kabeer Aziz | Director | 436,648 |
| Stephanie Wong | Director | – |
| Melvin K. Spigelman | Director | – |
Employees
Headcount reported in annual reports
“As of March 17, 2026, we had 21 full-time employees, consisting of research, manufacturing, clinical operations, quality, finance, and operational personnel.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Aug 19, 2024 | Listing | Registration of securities on an exchange (Form 8-A) |
| Mar 28, 2022 | IPO | Initial public offering priced (424B4 prospectus) |
| Mar 22, 2022 | Listing | Registration of securities on an exchange (Form 8-A) |